Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Next Previous
X
Search
Trial Profile

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Hyaluronidase; Pegfilgrastim; Prednisolone; Rituximab; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 29 May 2024 Planned End Date changed from 31 Dec 2028 to 30 Sep 2027.
    • 29 May 2024 Planned primary completion date changed from 31 Dec 2028 to 30 Sep 2027.
    • 26 Sep 2023 Time frame changed from up to 5 years to up to 7 years.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top